

**Testimony of Chad Grignon in Support of LD 890, An Act to Permit the
Dispensing of Ivermectin Pursuant to a Standing Order upon Request for
COVID-19, Flu and Cancer Patients**

May 1, 2025

Good morning, Senator Bailey, Representative Mathieson, and esteemed members of the Joint Standing Committee on Health Coverage, Insurance and Financial Services. I am here this morning in support of LD 890, *An Act to Permit the Dispensing of Ivermectin Pursuant to a Standing Order upon Request for COVID-19, Flu and Cancer Patients*.

My name is Chad Grignon. I own and operate my water well drilling business in Athens, Maine and manage 6 employees. I also served in the Maine State legislature for 3 consecutive terms.

A quick background on why I support the use of Ivermectin:

In 2012, at the age of 39, I was diagnosed with colon cancer. I followed the protocol of treatment with hopes to rid my body of this disease and was successful after numerous and difficult treatments.

Unfortunately, I was soon diagnosed with Non-Hodgkin follicular lymphoma, which has no cure at this time. I further endured more chemotherapy treatments to reduce the disease.

I learned about the benefits of Ivermectin from a childhood friend who had eliminated kidney cancer before needing surgery or treatment from its use. At this point there were not many options except to wait for the next round of treatments. I learned there was very little risk but that I needed to obtain safe Ivermectin from a reliable source.

I began a regimen and went to my first appointment after use to discover my cancer was headed to remission. Was this a fluke or the placebo effect? I find it unlikely.

My next visit was more good news and the decision was made to remove my port catheter. At my most recent appointment the decision was made to go to 12 month visits vs the six month CT scans that are standard of care for cancer patients.

I recommended Ivermectin to a dear friend who had stage 4 lung cancer and was a non-smoker in her 40s. After a short period of use, her tumor had disappeared. This left her oncologist in disbelief. Her almost certain death sentence was no longer a possibility.

My family was recently blindsided with the diagnosis of my little sister, who we unfortunately lost, from an aggressive form of small bowel carcinoma. I can only imagine if I had a safe supply of Ivermectin to administer while she was in the hospital that this could have prevented her untimely death.

At this time numerous Mainers are acquiring Ivermectin through mail orders from India or South America. We need to pass this bill to provide ensure a safe and secure supply of this medicine for Maine people just wanting another chance.

The potential approval for the sale of Ivermectin in Maine will be part of our ongoing battle against cancer. I believe it can provide a new hope. This is a decision that could mark a significant turning point in how we approach cancer treatments within our state. As we deliberate on this matter, it is essential to consider the reasons and scientific developments that could justify such approval.

Firstly, it is crucial to acknowledge the innovative spirit of medical research that continuously seeks to expand the range of available treatments. Recent studies have demonstrated promising results concerning the application of Ivermectin, traditionally used as an antiparasitic drug, in the realm of oncology. Research findings have indicated its potential efficacy in inhibiting the proliferation of certain cancer cells, showcasing a glimmer of hope in the fight against this devastating disease. In staying true to our commitment to advancing medical science, exploring and adopting promising new treatments could be a pivotal step in our healthcare evolution.

Moreover, the people of Maine deserve access to cutting-edge treatments which may provide them with more options and hope in their battle against cancer. Supporting the sale of Ivermectin for cancer treatment reinforces our dedication to providing residents with the best possible healthcare, alleviating their burdens, and improving their quality of life. By embracing emerging therapies, we express solidarity with our medical community in their relentless pursuit of novel solutions.

Additionally, it is essential to control the parameters around which Ivermectin would be sold and used. Implementing strict guidelines alongside robust clinical trials will safeguard public health, ensuring that this drug is administered accurately, effectively, and safely within its proposed new role. Such measures will ensure that risks are minimized and that patients benefit in the most responsible manner.

However, I must also acknowledge the importance of balanced decision-making. It is vital to consider all scientific evidence, consult with healthcare professionals, and actively engage in thorough analysis before making a decisive move.

In conclusion, as you reflect on this proposal, imagine the future we might craft—a future where Maine stands at the forefront of fighting cancer with innovation and hope. Let us make informed choices in advancing our medical landscape, offering our citizens new possibilities for health and healing. Thank you for your attention and consideration.